Antimycobacterial activity of cyclic dipeptides isolated from Bacillus sp. N strain associated with entomopathogenic nematode

References

• Anto RJ, Venkataraman M, Karunagaran D. (2003). Inhibition of NF-κB sensitizes A431 cells to epidermal growth factor-induced apoptosis, whereas its activation by ectopic expression of RelA confers resistance. J Biol Chem 28:25490–8
   Google Scholar
• Burnell AM, Stock SP. (2000). Heterorhabditis, Steinernema and their bacterial symbionts – Lethal pathogens of insects. Nematol 2:31–42
   Web of Science ®Google Scholar
• Centre for Disease Control. (2005). Worldwide emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs. Morb Mortal Wkly Rep 55:250–3
   Google Scholar
• CLSI, Clinical and Laboratory Standards Institute. (2012a). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-ninth edition. CLSI documents M07-A9. West Valley Road, Suite 2500, Wayne, PA 19087, USA
   Google Scholar
• CLSI, Clinical and Laboratory Standards Institute. (2012b). Performance standards for antimicrobial disk susceptibility tests; approved standard-eleventh edition. CLSI documents M02-A11. West Valley Road, Suite 2500, Wayne, PA 19087, USA
   Google Scholar
• Forst S, Nealson KH. (1996). Molecular biology of the symbiotic-pathogenic bacteria Xenorhabdus spp and Photorhabdus spp. Microbiology 51:47–57
   Google Scholar
• Gandhi NR, Nunn P, Dheda K, et al. (2010). Multidrug resistant and extensively drug-resistant tuberculosis: A threat to global control of tuberculosis. Lancet 375:1830–43
   PubMed Web of Science ®Google Scholar
• Goldman RC, Plumley KV, Laughon BE. (2007). The evolution of extensively drug resistant tuberculosis (XDR-TB): History, status and issues for global control. Infect Disord Drug Targets 7:73–91
   PubMedGoogle Scholar
• Graz C, Grant G, Brauns S, et al. (2000). Cyclic dipeptides in the induction of maturation for cancer therapy. J Pharmacy Pharmacol 52:75–82
   PubMed Web of Science ®Google Scholar
• Houston D, Synstad B, Eijsink V, et al. (2004). Structure-based exploration of cyclic dipeptide chitinase inhibitors. J Med Chem 47:5713–20
   PubMed Web of Science ®Google Scholar
• Janin YL. (2007). Antituberculosis drugs: Ten years of research. Bioorg Med Chem 15:2479–513
   PubMed Web of Science ®Google Scholar
• Kelecom A. (2002). Secondary metabolites from marine microorganisms. Ann Brazil Acad Sci 74:151–70
   PubMed Web of Science ®Google Scholar
• Krchnak V, Weichse AS, Cabe D, et al. (1996). Structurally homogeneous and heterogeneous synthetic combinatorial libraries. Mol Divers 1:149–64
   PubMed Web of Science ®Google Scholar
• Kumar NS, Mohandas C, Nambisan B, et al. (2012a). Isolation of proline-based cyclic dipeptides from Bacillus sp. N strain associated with a novel rhabitid entomopathogenic nematode and its antimicrobial properties. W J Microbiol Biotechnol 29:355–64
   PubMed Web of Science ®Google Scholar
• Kumar NS, Mohandas C, Siji JV, et al. (2012b). Identification of antimicrobial compound, diketopiperazines, from a Bacillus sp. N strain associated with a rhabditid entomopathogenic nematode against major plant pathogenic fungi. J Appl Microbiol 113:914–24
   PubMed Web of Science ®Google Scholar
• Kwon OS, Park SH, Yun BS, et al. (2000). Cyclo(dehydroala-l-Leu), an-glucosidase inhibitor from Penicillium sp. F70614. J Antibiot 53:954–8
   PubMed Web of Science ®Google Scholar
• Martin MB, Carvalho I. (2007). Diketopiperazines: Biological activity and synthesis. Tetrahedron 63:9923–32
   Web of Science ®Google Scholar
• Migliori GB, Sotgiu G. (2010). XDR tuberculosis in South Africa: Old questions, new answers. Lancet 375:1760–1
   PubMed Web of Science ®Google Scholar
• Milne PJ, Hunt AL, Rostoll K, et al. (1998). The biological activity of selected cyclic dipeptides. J Pharmacy Pharmacol 50:1331–7
   PubMed Web of Science ®Google Scholar
• NCCLS, National Committee for Clinical Laboratory Standards. (1999). Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guidelines, M26-A, vol. 19. Wayne, PA: National Committee for Clinical Laboratory Standards
   Google Scholar
• Newman DJ, Cragg GM. (2007). Natural products as sources of new drugs over the last 25 years. J Nat Prod 70:461–77
   PubMed Web of Science ®Google Scholar
• Nicholson B, Lloyd GK, Miller BR, et al. (2006). NPI-2358 is a tubulin-depolymerizing agent: In-vitro evidence for activity as a tumor vascular-disrupting agent. Anti-Cancer Drugs 17:25–31
   PubMed Web of Science ®Google Scholar
• Pauli GF, Case RJ, Inui T, et al. (2005). New perspectives on natural products in TB drug research. Life Sci 78:485–94
   PubMed Web of Science ®Google Scholar
• Peloquin CA, Nitta AT, Burman WJ, et al. (1996). Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother 30:919–25
   PubMed Web of Science ®Google Scholar
• Rhee KH. (2002). Isolation and characterization of Streptomyces sp. KH-614 producing anti-VRE (vancomycin-resistant enterococci) antibiotics. J Gen Appl Microbiol 48:327–31
   Web of Science ®Google Scholar
• Sanjay MJ. (2004). An important source for antitubercular drugs. Natural Prod 5:1–7
   Google Scholar
• Sinha S, Srivastava R, De Clercq E, Singh RK. (2004). Synthesis and antiviral properties of arabino and ribonucleosides of 1,3-dideazaadenine, 4-nitro-1,3-dideazapurine and diketopiperazine. Nucleos Nucleot Nucl 23:1815–24
   PubMed Web of Science ®Google Scholar
• Yang L, Tan R, Wang Q, et al. (2002). Antifungal cyclopeptides from Halobacillus litoralis YS3106 of marine origin. Tetrahedron Lett 43:6545–8
   Web of Science ®Google Scholar
• Zasloff M. (2002). Antimicrobial peptides of multicellular organisms. Nature 415:389–95
   PubMed Web of Science ®Google Scholar